Skip to main content

Table 4 Comparison of BCVA at each visit

From: Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial

BCVA (logMAR)

IVR group (n = 44)

IVC group (n = 46)

P value

Baseline

1.50 ± 0.70

1.51 ± 0.52

0.939

Postoperative 1 week

1.24 ± 0.63

1.29 ± 0.61

0.669

Postoperative 1 month

1.10 ± 0.63

1.14 ± 0.55

0.741

Postoperative 3 months

0.95 ± 0.58

0.99 ± 0.48

0.717

  1. logMAR = logarithm of minimum angle of resolution; BCVA = best-corrected visual acuity; IVR = intravitreal ranibizumab; IVC = intravitreal conbercept
Back to article page

Eye and Vision

ISSN: 2326-0254